China Health Industries Holdings, Inc. (CHHE) EBITDA (2017 - 2024)
China Health Industries Holdings (CHHE) has disclosed EBITDA for 13 consecutive years, with -$107878.0 as the latest value for Q1 2024.
- For the quarter ending Q1 2024, EBITDA rose 4.02% year-over-year to -$107878.0, compared with a TTM value of -$3.6 million through Mar 2024, down 27.4%, and an annual FY2023 reading of -$3.7 million, down 87.29% over the prior year.
- EBITDA was -$107878.0 for Q1 2024 at China Health Industries Holdings, up from -$242400.0 in the prior quarter.
- Across five years, EBITDA topped out at $2.6 million in Q4 2020 and bottomed at -$3.0 million in Q3 2022.
- Average EBITDA over 5 years is -$31066.1, with a median of -$74961.0 recorded in 2021.
- Peak annual rise in EBITDA hit 3029.15% in 2022, while the deepest fall reached 4252.62% in 2022.
- Year by year, EBITDA stood at $2.6 million in 2020, then plummeted by 102.94% to -$74961.0 in 2021, then surged by 3029.15% to $2.2 million in 2022, then tumbled by 111.04% to -$242400.0 in 2023, then skyrocketed by 55.5% to -$107878.0 in 2024.
- Business Quant data shows EBITDA for CHHE at -$107878.0 in Q1 2024, -$242400.0 in Q4 2023, and -$421592.0 in Q3 2023.